Deutsche Bank Downgrades MorphoSys to Hold
Deutsche Bank downgrades MorphoSys (NASDAQ:MOR) from Buy to Hold.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
48 Stocks Moving In Monday’s Mid-Day Session
Gainers
Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The stock is also trading higher in sympathy with the price of Bitcoin.
MorphoSys Stock Falls After Trimming Upper End Of 2021 Revenue Outlook
MorphoSys AG (NASDAQ:MOR) expects group revenues of €155 million to €180 million (previously: €150 to € 200 million, provided on March…
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 20)
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 64 stocks made new 52-week lows.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.